ClinicalTrials.gg
CompletedNCT02969044Updated Dec 4, 2018Results posted

Study To Assess The Efficacy And Safety Of Pf-06651600 In Subjects With Rheumatoid Arthritis With An Inadequate Response To Methotrexate

A Phase 2 interventional study of Placebo and PF-06651600 in Rheumatoid Arthritis, sponsored by Pfizer. Completed at 30 sites in 9 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2018-12-04.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 152 studies in Arthritis, Rheumatoid by Pfizer — 2 open to participants now, 2 under way, none of them phase 3. Arthritis, Rheumatoid · Pfizer.

Enrollment
59th of 86
70 · median 155
Started
2016
with 4 others
Phase 2
28 of 152
none open now
Registered
124th of 152
by date

Among the 152 studies in Arthritis, Rheumatoid by Pfizer, this one is the 59th largest by enrollment of the 86 interventional ones that give a count, is one of 5 that started in 2016, is one of 28 in phase 2, and was the 124th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

2 of the 152 studies in Arthritis, Rheumatoid by Pfizer are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 152 studies in Arthritis, Rheumatoid by Pfizer, or all of them as a file.
02

Study summary

This is an 8 week study to assess the efficacy and safety profile of PF-06651600 in seropositive subjects with rheumatoid arthritis with an inadequate response to methotrexate (up to approximately 50% of subjects may also have had an inadequate response to 1 anti-TNF biologic).

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects between the ages of 18 and 75 years, inclusive
  • Must have moderate-to-severe, active Rheumatoid Arthritis
  • Must have had an inadequate response to Methotrexate
  • Subjects may have received one approved TNF inhibiting biologic agent that was inadequately effective and/or not tolerated

Exclusion criteria

Exclusion Criteria

  • Subjects with any acute or chronic infections or infection history
  • Have acute or active chronic dermatological disorders prior to study start
  • Any major illness/condition(s) or evidence of an unstable clinical condition that in the judgment of the investigator would make the subject inappropriate for entry into this study
  • Known immunodeficiency disorder or a first degree relative with hereditary immunodeficiency
  • Any live (attenuated) vaccines or current routine household contact with anyone who has received live (attenuated) vaccine
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
70 participants (actual)

Study arms

  • Experimental
    PF-06651600

    Study Drug

    Drug: PF-06651600

  • Placebo comparator
    Placebo

    Placebo

    Drug: Placebo

Interventions

  • DrugPlacebo
  • 200mg pill every day (QD) for 8 weeks

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Simple Disease Activity Index (SDAI) Score at Week 8

    The SDAI is the numerical sum of five outcome parameters: tender joint count (TJC) and swollen joint count (SJC) based on a 28-joint assessment, patient global assessment (PtGA) and physician global assessment (PGA) assessed on a visual analogue scale (VAS) scale ranging from 0 to 10 centimeter (cm), where higher scores=greater affection due to disease activity, and C-reactive protein (CRP) measured in terms of milligram per deciliter (mg/dL). SDAI total score= 0 to 86. SDAI greater than or equal to (\<=) 3.3 indicates disease remission, greater than (\>) 3.4 to 11 = low disease activity, \>11 to 26 = moderate disease activity, and \>26 = high disease activity.

    Time frame: Baseline, Week 8

Secondary outcomes

  1. Number of Participants With Vital Signs Abnormalities

    Criteria: sitting pulse rate less than (\<) 40 beats per minute (bpm) or \>120 bpm; sitting systolic blood pressure (SBP) \>=30 millimeters of mercury (mmHg) change from baseline in same posture or \<90 mmHg; diastolic blood pressure (DBP) \>=20 mmHg change from baseline in same posture or \<50 mmHg. Only those categories in which at least one participant had abnormality, were reported in this outcome measure.

    Time frame: Baseline up to Week 12

  2. Number of Participants With Laboratory Abnormalities

    Hemoglobin(Hb);hematocrit;RBC count:\<0.8\*lower limit of normal (LLN),mean corpuscular volume;mean corpuscular Hb concentration:\<0.9\*LLN or\>1.1\*upper limit of normal (ULN), platelet:\<0.5\*LLN or \>1.75\*ULN,reticulocytes \<0.5\*LLN or \>1.5\*ULN,leukocytes \<0.6\*LLN or \>1.5\*ULN,lymphocyte;neutrophil: \<0.8\*LLN or \>1.2\*ULN,basophil;eosinophil; monocyte:\>1.2\*ULN,partial thromboplastin time,prothrombin time\>1.1\*ULN,bilirubin\>1.5\*ULN, aspartate aminotransferase; alanine aminotransferase;alkaline phosphatase:\>3.0\*ULN,protein;albumin;LDL, HDL cholesterol:\<0.8\*LLN or \>1.2\*ULN;urea nitrogen;creatinine: \>1.3\*ULN, urate \>1.2\*ULN, sodium\<0.95\*LLN or \>1.05\*ULN, potassium; chloride;calcium; bicarbonate:\<0.9\*LLN or \>1.1\*ULN,glucose \<0.6\*LLN or \>1.5\*ULN, creatine kinase: \>2.0\*ULN;urine pH \<4.5 or \>8,urine glucose or ketones\>=1,urine protein;urineHb\>=1,urobilinogen;bilirubin;nitrite;leukocyte esterase \>=1,urine erythrocytes, leukocytes\>=20,hyaline cast\>1,bacteria\>20.

    Time frame: Baseline up to Week 12

  3. Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to Week 12 that were absent before treatment or that worsened relative to pretreatment state.

    Time frame: Baseline up to Week 12

  4. Change From Baseline in Simple Disease Activity Index (SDAI) Score at Week 1, 2, 4 and 6

    The SDAI is the numerical sum of five outcome parameters: TJC and SJC based on a 28-joint assessment, PtGA and PGA assessed on a VAS scale ranging from 0 to 10 cm, where higher scores=greater affection due to disease activity, and CRP measured in terms of mg/dL. SDAI total score= 0 to 86. SDAI \<=3.3 indicates disease remission, \>3.4 to 11 = low disease activity, \>11 to 26 = moderate disease activity, and \>26 = high disease activity.

    Time frame: Baseline, Week 1, 2, 4 and 6

  5. Remission Rate Based on Simple Disease Activity Index Score

    Remission rate was defined as percentage of participants with disease remission. The SDAI is the numerical sum of five outcome parameters: TJC and SJC based on a 28-joint assessment, PtGA and PGA assessed on a VAS scale ranging from 0 to 10 cm, where higher scores=greater affection due to disease activity, and CRP measured in terms of mg/dL. SDAI total score= 0 to 86. SDAI \<=3.3 indicates disease remission, \>3.4 to 11 = low disease activity, \>11 to 26 = moderate disease activity, and \>26 = high disease activity.

    Time frame: Week 4, 6 and 8

  6. Remission Rate Based on Disease Activity Score (DAS28-3 [ESR])

    Remission rate was defined as the percentage of participants with disease remission. DAS28 is measure of disease activity in participants with rheumatoid arthritis. DAS28-3 (ESR) was calculated from SJC and TJC using 28 joints count, and erythrocyte sedimentation rate (ESR) (millimeters per hour \[mm/hr\]). Total score range: 0-9.4, higher score=more disease activity. DAS28-3 (ESR) \<= 3.2 implied low disease activity and \>3.2 to 5.1 implied moderate to high disease activity, and DAS28-3 (ESR) \<2.6 = remission.

    Time frame: Week 4, 6 and 8

  7. Remission Rate Based on Disease Activity Score (DAS28-4[ESR])

    Remission rate was defined as the percentage of participants with disease remission. DAS28 is measure of disease activity in participants with rheumatoid arthritis. DAS28-4 (ESR) was calculated from the number of SJC and TJC using the 28 joints count, the ESR (mm/hour) and participant's global assessment (PGA) of disease activity (participant rated arthritis activity assessment with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). Total score range: 0-9.4, higher score=more disease activity. DAS28-4 (ESR) \<= 3.2 implied low disease activity and \>3.2 to 5.1 implied moderate to high disease activity, and DAS28-4 (ESR) \<2.6 = remission.

    Time frame: Week 4, 6 and 8

  8. Remission Rate Based on Disease Activity Score (DAS28-3 [CRP])

    Remission rate was defined as the percentage of participants with disease remission. DAS28 is measure of disease activity in participants with rheumatoid arthritis. DAS28-3 (CRP) was calculated from the SJC and TJC using the 28 joints count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) \<= 3.2 implied low disease activity and \>3.2 to 5.1 implied moderate to high disease activity, and DAS28-3 (CRP) \<2.6 = remission.

    Time frame: Week 4, 6 and 8

  9. Remission Rate Based on Disease Activity Score (DAS28-4 [CRP])

    Remission rate was defined as the percentage of participants with disease remission. DAS28 is measure of disease activity in participants with rheumatoid arthritis. DAS28-4 (CRP): calculated from SJC, TJC, CRP (mg/L) and PGA (participant rated disease activity on VAS from 0 to 100 mm; high score=worse health). Total score range of DAS28-4 (CRP): 0 to 9.4(0=no activity; 9.4=extreme disease activity), higher score=more disease activity. DAS28-4(CRP) \<2.6=remission, \<3.2=low disease activity, \>=3.2-5.1=moderate disease activity and \>5.1=high disease activity.

    Time frame: Week 4, 6 and 8

  10. Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (3 Variables) (DAS28-3 [ESR]) at Week 1, 2, 4, 6 and 8

    DAS28 is measure of disease activity in participants with rheumatoid arthritis. DAS28-3 (ESR) was calculated from SJC and TJC using 28 joints count, and ESR (mm/hr). Total score range: 0-9.4, higher score=more disease activity. DAS28-3 (ESR) \<= 3.2 implied low disease activity and \>3.2 to 5.1 implied moderate to high disease activity, and DAS28-3 (ESR) \<2.6 = remission.

    Time frame: Baseline, Week 1, 2, 4, 6 and 8

  11. Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 1, 2, 4, 6 and 8

    DAS28 is measure of disease activity in participants with rheumatoid arthritis. DAS28-4 (ESR) was calculated from SJC and TJC using 28 joints count, ESR (mm/hr) and PtGA of disease activity (participant rated arthritis activity assessment). Total score range: 0-9.4, higher score=more disease activity. DAS28-4 (ESR) \<= 3.2 implied low disease activity and \>3.2 to 5.1 implied moderate to high disease activity, and DAS28-4 (ESR) \<2.6 = remission.

    Time frame: Baseline, Week 1, 2, 4, 6 and 8

  12. Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 1, 2, 4, 6 and 8

    DAS28 is measure of disease activity in participants. DAS28-3 (CRP) was calculated from the SJC and TJC using the 28 joints count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) \<= 3.2 implied low disease activity and \>3.2 to 5.1 implied moderate to high disease activity, and DAS28-3 (CRP) \<2.6 = remission.

    Time frame: Baseline, Week 1, 2, 4, 6 and 8

  13. Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (4 Variables) (DAS28-4 [CRP]) at Week 1, 2, 4, 6 and 8

    DAS28 is measure of disease activity in participants. DAS28-4 (CRP): calculated from SJC, TJC, CRP(mg/L) and PGA (participant rated disease activity on VAS from 0 to 100 mm; high score=worse health). Total score range of DAS28-4 (CRP): 0 to 9.4(0=no activity; 9.4=extreme disease activity), higher score=more disease activity. DAS28-4(CRP) \<2.6=remission, \<3.2=low disease activity, \>=3.2-5.1=moderate disease activity and \>5.1=high disease activity.

    Time frame: Baseline, Week 1, 2, 4, 6 and 8

  14. Change From Baseline in High Sensitivity C-Reactive Protein (hsCRP) Concentration at Week 1, 2, 4, 6 and 8

    Time frame: Baseline, Week 1, 2, 4, 6 and 8

  15. Change From Baseline in the Tender Joint Count and Swollen Joint Count at Week 1, 2, 4, 6 and 8

    Tender joint count was an assessment of 68 joints (upper body, upper extremity, and lower extremity). Each joint's response to pressure/motion was assessed as: Present or Absent. Swollen joint count was an assessment of 66 joints (upper body, upper extremity, and lower extremity). Each joint was assessed for swelling as: Present or Absent.

    Time frame: Baseline, Week 1, 2, 4, 6 and 8

  16. Change From Baseline in Participant's Assessment of Arthritis Pain (PAAP), Participant's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 1, 2, 4, 6 and 8

    PAAP: Participants assessed the severity of their arthritis pain by using a 100 mm VAS ranging from 0 (no pain) to 100 (most severe pain), which corresponded to the magnitude of their pain, where higher scores indicated more pain. PGA: Participants were asked the following question, "Considering all the ways your arthritis affects you, how are you feeling today?" and their response was recorded on a 100 mm VAS ranging from 0 (very well) to 100 (very poor), where higher scores indicated worse health condition. PGAA: Participants were assessed how their overall arthritis appears at the time of the visit. The evaluation was based on the participant's disease signs, functional capacity and physical examination, and was independent of the PAAP and PGA assessments. The physician's response was recorded using a 100 mm VAS ranging from 0 (very well) to 100 (very poor), where higher scores indicated more disease activity.

    Time frame: Baseline, Week 1, 2, 4, 6 and 8

  17. Change From Baseline in Health Assessment Questionnaire-Disability Index [HAQ-DI] at Week 1, 2, 4, 6 and 8

    HAQ-DI assess degree of difficulty a participant experienced (during past week) in 8 domain of daily activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip and other activities. Each item scored on a 4-point scale ranging from 0 to 3(0=no difficulty; 3=extreme difficulty). Overall score: average of the sum of domain scores/number of domains answered. Total possible score range (0=least difficulty; 3=extreme difficulty); high scores=more difficulty in performing daily living activities.

    Time frame: Baseline, Week 1, 2, 4, 6 and 8

07

Results

Posted Dec 4, 2018

Participant flow

Participant flow — Overall Study
MilestonePF-06651600Placebo
Started4228
Completed3722
Not completed56
Withdrew: Withdrawal by subject26
Withdrew: Adverse event30

Outcome measures

PrimaryChange From Baseline in Simple Disease Activity Index (SDAI) Score at Week 8

The SDAI is the numerical sum of five outcome parameters: tender joint count (TJC) and swollen joint count (SJC) based on a 28-joint assessment, patient global assessment (PtGA) and physician global assessment (PGA) assessed on a visual analogue scale (VAS) scale ranging from 0 to 10 centimeter (cm), where higher scores=greater affection due to disease activity, and C-reactive protein (CRP) measured in terms of milligram per deciliter (mg/dL). SDAI total score= 0 to 86. SDAI greater than or equal to (\<=) 3.3 indicates disease remission, greater than (\>) 3.4 to 11 = low disease activity, \>11 to 26 = moderate disease activity, and \>26 = high disease activity.

Time frame:
Baseline, Week 8
Reported as:
Mean · units on a scale
Change From Baseline in Simple Disease Activity Index (SDAI) Score at Week 8
units on a scalePF-06651600Placebo
Baseline45.15 ± 13.16444.85 ± 13.976
Change at Week 8-26.11 ± 14.834-17.38 ± 18.176
Statistical analysis
  • PF-06651600 vs Placebo · ANCOVA · p = <0.001 · Mean difference (net): -9.25 · 95% CI -14.75 to -3.79
SecondaryNumber of Participants With Vital Signs Abnormalities

Criteria: sitting pulse rate less than (\<) 40 beats per minute (bpm) or \>120 bpm; sitting systolic blood pressure (SBP) \>=30 millimeters of mercury (mmHg) change from baseline in same posture or \<90 mmHg; diastolic blood pressure (DBP) \>=20 mmHg change from baseline in same posture or \<50 mmHg. Only those categories in which at least one participant had abnormality, were reported in this outcome measure.

Time frame:
Baseline up to Week 12
Reported as:
Count of participants · Participants
Number of Participants With Vital Signs Abnormalities
ParticipantsPF-06651600Placebo
Sitting DBP >=20 mmHg increase from baseline30
Sitting DBP >=20 mmHg decrease from baseline01
SecondaryNumber of Participants With Laboratory Abnormalities

Hemoglobin(Hb);hematocrit;RBC count:\<0.8\*lower limit of normal (LLN),mean corpuscular volume;mean corpuscular Hb concentration:\<0.9\*LLN or\>1.1\*upper limit of normal (ULN), platelet:\<0.5\*LLN or \>1.75\*ULN,reticulocytes \<0.5\*LLN or \>1.5\*ULN,leukocytes \<0.6\*LLN or \>1.5\*ULN,lymphocyte;neutrophil: \<0.8\*LLN or \>1.2\*ULN,basophil;eosinophil; monocyte:\>1.2\*ULN,partial thromboplastin time,prothrombin time\>1.1\*ULN,bilirubin\>1.5\*ULN, aspartate aminotransferase; alanine aminotransferase;alkaline phosphatase:\>3.0\*ULN,protein;albumin;LDL, HDL cholesterol:\<0.8\*LLN or \>1.2\*ULN;urea nitrogen;creatinine: \>1.3\*ULN, urate \>1.2\*ULN, sodium\<0.95\*LLN or \>1.05\*ULN, potassium; chloride;calcium; bicarbonate:\<0.9\*LLN or \>1.1\*ULN,glucose \<0.6\*LLN or \>1.5\*ULN, creatine kinase: \>2.0\*ULN;urine pH \<4.5 or \>8,urine glucose or ketones\>=1,urine protein;urineHb\>=1,urobilinogen;bilirubin;nitrite;leukocyte esterase \>=1,urine erythrocytes, leukocytes\>=20,hyaline cast\>1,bacteria\>20.

Time frame:
Baseline up to Week 12
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Abnormalities
ParticipantsPF-06651600Placebo
Number of Participants With Laboratory Abnormalities4228
SecondaryNumber of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to Week 12 that were absent before treatment or that worsened relative to pretreatment state.

Time frame:
Baseline up to Week 12
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsPF-06651600Placebo
AEs205
SAEs00
SecondaryChange From Baseline in Simple Disease Activity Index (SDAI) Score at Week 1, 2, 4 and 6

The SDAI is the numerical sum of five outcome parameters: TJC and SJC based on a 28-joint assessment, PtGA and PGA assessed on a VAS scale ranging from 0 to 10 cm, where higher scores=greater affection due to disease activity, and CRP measured in terms of mg/dL. SDAI total score= 0 to 86. SDAI \<=3.3 indicates disease remission, \>3.4 to 11 = low disease activity, \>11 to 26 = moderate disease activity, and \>26 = high disease activity.

Time frame:
Baseline, Week 1, 2, 4 and 6
Reported as:
Mean · units on a scale
Change From Baseline in Simple Disease Activity Index (SDAI) Score at Week 1, 2, 4 and 6
units on a scalePF-06651600Placebo
Change at Week 1-4.59 ± 9.409-4.52 ± 7.025
Change at Week 2-12.82 ± 10.969-8.05 ± 9.402
Change at Week 4-17.79 ± 12.804-12.55 ± 13.462
Change at Week 6-22.79 ± 14.007-15.62 ± 14.231
SecondaryRemission Rate Based on Simple Disease Activity Index Score

Remission rate was defined as percentage of participants with disease remission. The SDAI is the numerical sum of five outcome parameters: TJC and SJC based on a 28-joint assessment, PtGA and PGA assessed on a VAS scale ranging from 0 to 10 cm, where higher scores=greater affection due to disease activity, and CRP measured in terms of mg/dL. SDAI total score= 0 to 86. SDAI \<=3.3 indicates disease remission, \>3.4 to 11 = low disease activity, \>11 to 26 = moderate disease activity, and \>26 = high disease activity.

Time frame:
Week 4, 6 and 8
Reported as:
Number · percentage of participants
Remission Rate Based on Simple Disease Activity Index Score
percentage of participantsPF-06651600Placebo
Week 44.80.0
Week 64.80.0
Week 87.10.0
SecondaryRemission Rate Based on Disease Activity Score (DAS28-3 [ESR])

Remission rate was defined as the percentage of participants with disease remission. DAS28 is measure of disease activity in participants with rheumatoid arthritis. DAS28-3 (ESR) was calculated from SJC and TJC using 28 joints count, and erythrocyte sedimentation rate (ESR) (millimeters per hour \[mm/hr\]). Total score range: 0-9.4, higher score=more disease activity. DAS28-3 (ESR) \<= 3.2 implied low disease activity and \>3.2 to 5.1 implied moderate to high disease activity, and DAS28-3 (ESR) \<2.6 = remission.

Time frame:
Week 4, 6 and 8
Reported as:
Number · percentage of participants
Remission Rate Based on Disease Activity Score (DAS28-3 [ESR])
percentage of participantsPF-06651600Placebo
Week 44.80.0
Week 62.40.0
Week 87.10.0
SecondaryRemission Rate Based on Disease Activity Score (DAS28-4[ESR])

Remission rate was defined as the percentage of participants with disease remission. DAS28 is measure of disease activity in participants with rheumatoid arthritis. DAS28-4 (ESR) was calculated from the number of SJC and TJC using the 28 joints count, the ESR (mm/hour) and participant's global assessment (PGA) of disease activity (participant rated arthritis activity assessment with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). Total score range: 0-9.4, higher score=more disease activity. DAS28-4 (ESR) \<= 3.2 implied low disease activity and \>3.2 to 5.1 implied moderate to high disease activity, and DAS28-4 (ESR) \<2.6 = remission.

Time frame:
Week 4, 6 and 8
Reported as:
Number · percentage of participants
Remission Rate Based on Disease Activity Score (DAS28-4[ESR])
percentage of participantsPF-06651600Placebo
Week 44.80.0
Week 64.80.0
Week 87.10.0
SecondaryRemission Rate Based on Disease Activity Score (DAS28-3 [CRP])

Remission rate was defined as the percentage of participants with disease remission. DAS28 is measure of disease activity in participants with rheumatoid arthritis. DAS28-3 (CRP) was calculated from the SJC and TJC using the 28 joints count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) \<= 3.2 implied low disease activity and \>3.2 to 5.1 implied moderate to high disease activity, and DAS28-3 (CRP) \<2.6 = remission.

Time frame:
Week 4, 6 and 8
Reported as:
Number · percentage of participants
Remission Rate Based on Disease Activity Score (DAS28-3 [CRP])
percentage of participantsPF-06651600Placebo
Week 49.50.0
Week 67.13.6
Week 89.50.0
SecondaryRemission Rate Based on Disease Activity Score (DAS28-4 [CRP])

Remission rate was defined as the percentage of participants with disease remission. DAS28 is measure of disease activity in participants with rheumatoid arthritis. DAS28-4 (CRP): calculated from SJC, TJC, CRP (mg/L) and PGA (participant rated disease activity on VAS from 0 to 100 mm; high score=worse health). Total score range of DAS28-4 (CRP): 0 to 9.4(0=no activity; 9.4=extreme disease activity), higher score=more disease activity. DAS28-4(CRP) \<2.6=remission, \<3.2=low disease activity, \>=3.2-5.1=moderate disease activity and \>5.1=high disease activity.

Time frame:
Week 4, 6 and 8
Reported as:
Number · percentage of participants
Remission Rate Based on Disease Activity Score (DAS28-4 [CRP])
percentage of participantsPF-06651600Placebo
Week 49.50.0
Week 69.53.6
Week 89.50.0
SecondaryChange From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (3 Variables) (DAS28-3 [ESR]) at Week 1, 2, 4, 6 and 8

DAS28 is measure of disease activity in participants with rheumatoid arthritis. DAS28-3 (ESR) was calculated from SJC and TJC using 28 joints count, and ESR (mm/hr). Total score range: 0-9.4, higher score=more disease activity. DAS28-3 (ESR) \<= 3.2 implied low disease activity and \>3.2 to 5.1 implied moderate to high disease activity, and DAS28-3 (ESR) \<2.6 = remission.

Time frame:
Baseline, Week 1, 2, 4, 6 and 8
Reported as:
Mean · units on a scale
Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (3 Variables) (DAS28-3 [ESR]) at Week 1, 2, 4, 6 and 8
units on a scalePF-06651600Placebo
Baseline6.49 ± 0.7626.37 ± 0.815
Change at Week 1-0.19 ± 0.604-0.26 ± 0.434
Change at Week 2-0.67 ± 0.602-0.46 ± 0.531
Change at Week 4-1.16 ± 1.125-0.78 ± 0.905
Change at Week 6-1.54 ± 1.123-1.07 ± 0.989
Change at Week 8-1.85 ± 1.161-1.07 ± 1.214
SecondaryChange From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 1, 2, 4, 6 and 8

DAS28 is measure of disease activity in participants with rheumatoid arthritis. DAS28-4 (ESR) was calculated from SJC and TJC using 28 joints count, ESR (mm/hr) and PtGA of disease activity (participant rated arthritis activity assessment). Total score range: 0-9.4, higher score=more disease activity. DAS28-4 (ESR) \<= 3.2 implied low disease activity and \>3.2 to 5.1 implied moderate to high disease activity, and DAS28-4 (ESR) \<2.6 = remission.

Time frame:
Baseline, Week 1, 2, 4, 6 and 8
Reported as:
Mean · units on a scale
Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 1, 2, 4, 6 and 8
units on a scalePF-06651600Placebo
Baseline6.82 ± 0.8156.72 ± 0.880
Change at Week 1-0.27 ± 0.553-0.27 ± 0.477
Change at Week 2-0.83 ± 0.695-0.47 ± 0.551
Change at Week 4-1.36 ± 1.173-0.89 ± 0.951
Change at Week 6-1.81 ± 1.179-1.18 ± 1.050
Change at Week 8-2.14 ± 1.269-1.22 ± 1.448
SecondaryChange From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 1, 2, 4, 6 and 8

DAS28 is measure of disease activity in participants. DAS28-3 (CRP) was calculated from the SJC and TJC using the 28 joints count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) \<= 3.2 implied low disease activity and \>3.2 to 5.1 implied moderate to high disease activity, and DAS28-3 (CRP) \<2.6 = remission.

Time frame:
Baseline, Week 1, 2, 4, 6 and 8
Reported as:
Mean · units on a scale
Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 1, 2, 4, 6 and 8
units on a scalePF-06651600Placebo
Baseline5.76 ± 0.8245.61 ± 0.894
Change at Week 1-0.35 ± 0.741-0.20 ± 0.456
Change at Week 2-0.86 ± 0.782-0.47 ± 0.585
Change at Week 4-1.33 ± 1.219-0.72 ± 1.005
Change at Week 6-1.53 ± 1.286-1.01 ± 0.993
Change at Week 8-1.79 ± 1.265-1.03 ± 1.146
SecondaryChange From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (4 Variables) (DAS28-4 [CRP]) at Week 1, 2, 4, 6 and 8

DAS28 is measure of disease activity in participants. DAS28-4 (CRP): calculated from SJC, TJC, CRP(mg/L) and PGA (participant rated disease activity on VAS from 0 to 100 mm; high score=worse health). Total score range of DAS28-4 (CRP): 0 to 9.4(0=no activity; 9.4=extreme disease activity), higher score=more disease activity. DAS28-4(CRP) \<2.6=remission, \<3.2=low disease activity, \>=3.2-5.1=moderate disease activity and \>5.1=high disease activity.

Time frame:
Baseline, Week 1, 2, 4, 6 and 8
Reported as:
Mean · units on a scale
Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (4 Variables) (DAS28-4 [CRP]) at Week 1, 2, 4, 6 and 8
units on a scalePF-06651600Placebo
Baseline6.11 ± 0.8505.98 ± 0.926
Change at Week 1-0.41 ± 0.685-0.21 ± 0.473
Change at Week 2-0.99 ± 0.823-0.47 ± 0.574
Change at Week 4-1.49 ± 1.222-0.82 ± 1.013
Change at Week 6-1.78 ± 1.304-1.09 ± 1.057
Change at Week 8-2.06 ± 1.321-1.16 ± 1.367
SecondaryChange From Baseline in High Sensitivity C-Reactive Protein (hsCRP) Concentration at Week 1, 2, 4, 6 and 8
Time frame:
Baseline, Week 1, 2, 4, 6 and 8
Reported as:
Mean · milligram per deciliter
Change From Baseline in High Sensitivity C-Reactive Protein (hsCRP) Concentration at Week 1, 2, 4, 6 and 8
milligram per deciliterPF-06651600Placebo
Baseline2.00 ± 1.8161.68 ± 2.853
Change at Week 1-0.20 ± 2.6720.60 ± 2.263
Change at Week 2-0.62 ± 2.090-0.04 ± 0.966
Change at Week 4-0.93 ± 1.5910.00 ± 1.335
Change at Week 6-0.42 ± 2.376-0.23 ± 1.327
Change at Week 8-0.89 ± 2.142-0.04 ± 2.220
SecondaryChange From Baseline in the Tender Joint Count and Swollen Joint Count at Week 1, 2, 4, 6 and 8

Tender joint count was an assessment of 68 joints (upper body, upper extremity, and lower extremity). Each joint's response to pressure/motion was assessed as: Present or Absent. Swollen joint count was an assessment of 66 joints (upper body, upper extremity, and lower extremity). Each joint was assessed for swelling as: Present or Absent.

Time frame:
Baseline, Week 1, 2, 4, 6 and 8
Reported as:
Mean · joint count
Change From Baseline in the Tender Joint Count and Swollen Joint Count at Week 1, 2, 4, 6 and 8
joint countPF-06651600Placebo
Baseline: Tender joint count16.74 ± 6.76516.75 ± 6.681
Baseline: Swollen joint count12.95 ± 5.39612.11 ± 6.160
Change at Week 1: Tender joint count-1.54 ± 4.915-1.96 ± 2.701
Change at Week 1: Swollen joint count-1.49 ± 4.439-2.46 ± 3.501
Change at Week 2: Tender joint count-4.40 ± 5.522-2.56 ± 5.213
Change at Week 2: Swollen joint count-4.71 ± 4.430-4.11 ± 4.619
Change at Week 4: Tender joint count-6.76 ± 6.818-4.96 ± 7.750
Change at Week 4: Swollen joint count-5.95 ± 4.950-4.85 ± 4.961
Change at Week 6: Tender joint count-8.75 ± 7.132-6.42 ± 6.652
Change at Week 6: Swollen joint count-7.80 ± 5.743-5.85 ± 5.540
Change at Week 8: Tender joint count-10.21 ± 7.259-6.83 ± 7.755
Change at Week 8: Swollen joint count-8.59 ± 6.176-6.54 ± 6.324
SecondaryChange From Baseline in Participant's Assessment of Arthritis Pain (PAAP), Participant's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 1, 2, 4, 6 and 8

PAAP: Participants assessed the severity of their arthritis pain by using a 100 mm VAS ranging from 0 (no pain) to 100 (most severe pain), which corresponded to the magnitude of their pain, where higher scores indicated more pain. PGA: Participants were asked the following question, "Considering all the ways your arthritis affects you, how are you feeling today?" and their response was recorded on a 100 mm VAS ranging from 0 (very well) to 100 (very poor), where higher scores indicated worse health condition. PGAA: Participants were assessed how their overall arthritis appears at the time of the visit. The evaluation was based on the participant's disease signs, functional capacity and physical examination, and was independent of the PAAP and PGA assessments. The physician's response was recorded using a 100 mm VAS ranging from 0 (very well) to 100 (very poor), where higher scores indicated more disease activity.

Time frame:
Baseline, Week 1, 2, 4, 6 and 8
Reported as:
Mean · units on a scale
Change From Baseline in Participant's Assessment of Arthritis Pain (PAAP), Participant's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 1, 2, 4, 6 and 8
units on a scalePF-06651600Placebo
Baseline: PAAP66.64 ± 16.77171.75 ± 16.183
Baseline: PGA68.43 ± 15.63969.00 ± 16.115
Baseline: PGAA66.17 ± 14.22874.07 ± 12.844
Change at Week 1: PAAP-4.95 ± 11.388-2.86 ± 14.847
Change at Week 1: PGA-6.76 ± 11.128-1.93 ± 9.149
Change at Week 1: PGAA-6.83 ± 8.947-4.96 ± 8.126
Change at Week 2: PAAP-11.90 ± 18.061-6.04 ± 12.669
Change at Week 2: PGA-14.74 ± 15.963-2.81 ± 9.931
Change at Week 2: PGAA-16.07 ± 16.499-10.63 ± 12.500
Change at Week 4: PAAP-19.88 ± 16.695-10.23 ± 25.513
Change at Week 4: PGA-20.05 ± 13.746-12.12 ± 19.574
Change at Week 4: PGAA-21.49 ± 16.715-17.96 ± 18.877
Change at Week 6: PAAP-27.90 ± 20.061-12.35 ± 27.425
Change at Week 6: PGA-27.83 ± 18.936-11.65 ± 21.630
Change at Week 6: PGAA-30.45 ± 17.868-19.50 ± 22.963
Change at Week 8: PAAP-32.92 ± 25.051-18.58 ± 34.152
Change at Week 8: PGA-30.92 ± 21.279-15.88 ± 30.135
Change at Week 8: PGAA-33.28 ± 18.725-23.75 ± 25.902
SecondaryChange From Baseline in Health Assessment Questionnaire-Disability Index [HAQ-DI] at Week 1, 2, 4, 6 and 8

HAQ-DI assess degree of difficulty a participant experienced (during past week) in 8 domain of daily activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip and other activities. Each item scored on a 4-point scale ranging from 0 to 3(0=no difficulty; 3=extreme difficulty). Overall score: average of the sum of domain scores/number of domains answered. Total possible score range (0=least difficulty; 3=extreme difficulty); high scores=more difficulty in performing daily living activities.

Time frame:
Baseline, Week 1, 2, 4, 6 and 8
Reported as:
Mean · units on a scale
Change From Baseline in Health Assessment Questionnaire-Disability Index [HAQ-DI] at Week 1, 2, 4, 6 and 8
units on a scalePF-06651600Placebo
Baseline1.79 ± 0.5771.69 ± 0.550
Change at Week 1-0.13 ± 0.391-0.04 ± 0.316
Change at Week 2-0.26 ± 0.430-0.15 ± 0.347
Change at Week 4-0.39 ± 0.414-0.19 ± 0.534
Change at Week 6-0.46 ± 0.527-0.23 ± 0.609
Change at Week 8-0.53 ± 0.583-0.32 ± 0.671

Adverse events

Collected over Baseline up to Week 12. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PF-066516000/42 (0%)0/42 (0%)20/42 (47.6%)
Placebo0/28 (0%)0/28 (0%)5/28 (17.9%)
Most frequent other events
Showing 10 of 28
Most frequent other events
EventPF-06651600Placebo
HeadacheNervous system disorders0/423/28
LymphopeniaBlood and lymphatic system disorders3/420/28
InfluenzaInfections and infestations3/420/28
PruritusSkin and subcutaneous tissue disorders2/421/28
Upper respiratory tract infectionInfections and infestations0/421/28
Alanine aminotransferase increasedInvestigations0/421/28
Aspartate aminotransferase increasedInvestigations0/421/28
Spinal painMusculoskeletal and connective tissue disorders0/421/28
Abdominal distensionGastrointestinal disorders1/420/28
GlossitisGastrointestinal disorders1/420/28

Baseline characteristics

Intent to treat (ITT) analysis set included all participants who were randomized to the study and received at least one dose of the randomized investigational drug (PF-06651600 or placebo).

Age, Continuous
Age, Continuous(years)PF-06651600PlaceboTotal
Mean55.4 ± 11.7254.2 ± 11.7854.9 ± 11.67
Sex: Female, Male
Sex: Female, Male(Participants)PF-06651600PlaceboTotal
Female332457
Male9413
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PF-06651600PlaceboTotal
Hispanic or Latino123
Not Hispanic or Latino412667
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PF-06651600PlaceboTotal
American Indian or Alaska Native000
Asian101
Native Hawaiian or Other Pacific Islander000
Black or African American000
White412869
More than one race000
Unknown or Not Reported000
08

Study locations

30 sites
  • California Medical Research Associates Inc.
    Northridge, California 91324, United States
  • Clayton Medical Associates, PC
    Saint Louis, Missouri 63117, United States
  • Altoona Center For Clinical Research
    Duncansville, Pennsylvania 16635, United States
  • Southwest Rheumatology Research, LLC
    Mesquite, Texas 75150, United States
  • MHAT "Trimontsium" Department of Internal Diseases
    Plovdiv, 4000, Bulgaria
  • UMHAT Kaspela, Clinic of Rheumatology
    Plovdiv, 4001, Bulgaria
  • Medical Centre "Pirogov"
    Sofia, 1606, Bulgaria
  • Medical Center Equita
    Varna, 9000, Bulgaria
  • Medical Center "Sveti Ivan Rilski"
    Vidin, 3700, Bulgaria
  • MEDICAL PLUS, s.r.o.
    Uherske Hradiste, 686 01, Czechia
  • LTD "Unimed Ajara" Batumi Referral Hospital
    Batumi, 6010, Georgia
  • LTD Israeli-Georgian Medical Research Clinic ,,Helsicore"
    Tbilisi, 0112, Georgia
  • Ltd Institute of Clinical Cardiology
    Tbilisi, 0159, Georgia
  • LTD Unimedi Kakheti
    Tbilisi, 0159, Georgia
  • ISA - Interdisciplinary Study Association GmbH
    Berlin, 10789, Germany
  • Rheumatologische Schwerpunktpraxis
    Berlin, 12161, Germany
  • Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz, Klinikai Kutatasi Osztaly
    Nyiregyhaza, H-4400, Hungary
  • NZOZ Centrum Medyczne Sw. Lukasza w Kartuzach
    Kartuzy, 83-300, Poland
  • Care Clinic Sp. z o.o.
    Katowice, 40-060, Poland
  • Silmedic Sp. z o.o. Oddzial w Katowicach
    Katowice, 40-282, Poland
  • Oswiecimskie Centrum Badan Klinicznych Medicome Sp. z o.o.
    Oswiecim, 32-600, Poland
  • Centrum Medyczne Oporow
    Wroclaw, 52-416, Poland
  • Clinic of Dermatovenerology "Prof. Zecevic"
    Belgrade, 11000, Serbia
  • Institute of Rheumatology
    Belgrade, 11000, Serbia
  • Polyclinic Medikom
    Belgrade, 11000, Serbia
  • Institute of Treatment and Rehabilitation "Niska Banja"
    Niska Banja, 18205, Serbia
  • AAGS s.r.o., Reumatologicka ambulancia
    Dunajska Streda, 92901, Slovakia
  • MUDr. Zuzana Cizmarikova s.r.o. , Reumatologicka ambulancia
    Poprad, 058 01, Slovakia
  • Nestatna reumatologicka ambulancia
    Povazska Bystrica, 017 01, Slovakia
  • Reumatologicka ambulancia, MUDr. Pavol Polak s.r.o.
    Zilina, 01001, Slovakia
09

References and documents

Publications

  • Robinson MF, Damjanov N, Stamenkovic B, Radunovic G, Kivitz A, Cox L, Manukyan Z, Banfield C, Saunders M, Chandra D, Vincent MS, Mancuso J, Peeva E, Beebe JS. Efficacy and Safety of PF-06651600 (Ritlecitinib), a Novel JAK3/TEC Inhibitor, in Patients With Moderate-to-Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate. Arthritis Rheumatol. 2020 Oct;72(10):1621-1631. doi: 10.1002/art.41316. Epub 2020 Sep 7. PubMed 32419304 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2016 to primary completion in Dec 2017, 11 months.

Results were first posted in Dec 2018, 11 months after primary completion.

Of 116 industry-sponsored phase 2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 24. This study's 11 months is below that.

Counting every sponsor, half of 158 studies reached it within 18 months; a quarter within 13 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2016
First posted
Nov 21, 2016
StartActual
Dec 20, 2016
Primary completionActual
Dec 12, 2017
CompletionActual
Dec 12, 2017
Results first posted
Dec 4, 2018
Last update
Dec 4, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 4, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02969044
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Nov 21, 2016
Start date
Dec 20, 2016
Primary completion
Dec 12, 2017
Completion
Dec 12, 2017
Results posted
Dec 4, 2018
Last update
Dec 4, 2018

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PF-06651600

Start the discussion